Replies to post #2093 on Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Yes.
But first is still first.
A functional cure (even a 50% cure) and being first would have it's benefits.

I'm not up on who else has an effective agent for the surface antigen, but such an agent and EDP-514 could achieve a functional cure ...or..... it might prove/suggest what else is missing for a functional HBV cure.

RE: your post on "pretty modest"; the volume isn't that compelling. I held, although I thought the drop could easily be in the 10% range.

I'm not saying either party can or should.
I'm just wondering what the next move will be and thinking of options- while not knowing what Enanta has in development- or their competitors.